Odimma Therapeutics announced the presentation of new preclinical data supporting ODI-2001, the company’s personalized combinatorial immunotherapy platform, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting held in Houston, Texas from November 6–10, 2024.
The data presented demonstrate antitumoral activity across multiple syngeneic mouse tumor models, including the highly aggressive 4T1 breast cancer model, further supporting the therapeutic potential of the ODI-2001 platform.
ODI-2001 combines AI-driven neoantigen selection, synthetic DNA technologies and personalized immune activation strategies designed to support next-generation precision oncology approaches.
Participation at SITC 2024 represents an important scientific and strategic milestone for Odimma Therapeutics, highlighting the company’s continued progress within the field of personalized cancer immunotherapy.
The Society for Immunotherapy of Cancer Annual Meeting is one of the leading global conferences dedicated to cancer immunotherapy research, bringing together biotechnology innovators, clinicians, researchers and industry leaders from across the oncology ecosystem.
Presentation Details
Presentation Number: 805
Immune Engineering Workshop Poster Session
Thursday, November 7, 2024
3:10 PM – 5:00 PM
Annual Meeting Poster Session
Friday, November 8, 2024.
